"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 4 | 5 |
| 1995 | 3 | 3 | 6 |
| 1996 | 4 | 3 | 7 |
| 1997 | 3 | 7 | 10 |
| 1998 | 6 | 5 | 11 |
| 1999 | 3 | 6 | 9 |
| 2000 | 4 | 7 | 11 |
| 2001 | 4 | 12 | 16 |
| 2002 | 12 | 13 | 25 |
| 2003 | 12 | 11 | 23 |
| 2004 | 8 | 12 | 20 |
| 2005 | 15 | 7 | 22 |
| 2006 | 12 | 14 | 26 |
| 2007 | 12 | 11 | 23 |
| 2008 | 12 | 21 | 33 |
| 2009 | 20 | 19 | 39 |
| 2010 | 20 | 18 | 38 |
| 2011 | 20 | 23 | 43 |
| 2012 | 16 | 20 | 36 |
| 2013 | 19 | 17 | 36 |
| 2014 | 39 | 21 | 60 |
| 2015 | 31 | 22 | 53 |
| 2016 | 46 | 40 | 86 |
| 2017 | 77 | 47 | 124 |
| 2018 | 88 | 48 | 136 |
| 2019 | 67 | 56 | 123 |
| 2020 | 108 | 72 | 180 |
| 2021 | 68 | 101 | 169 |
| 2022 | 14 | 134 | 148 |
| 2023 | 7 | 101 | 108 |
| 2024 | 40 | 62 | 102 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Perioperative Implications of Biologics and Immunotherapy. Adv Anesth. 2024 Dec; 42(1):97-113.
-
H2S-Prdx4 axis mitigates Golgi stress to bolster tumor-reactive T cell immunotherapeutic response. Sci Adv. 2024 Nov 15; 10(46):eadp1152.
-
CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells. Gut. 2024 Nov 11; 73(12):1984-1998.
-
WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy. J Immunother Cancer. 2024 Nov 05; 12(11).
-
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro Oncol. 2024 Nov 04; 26(11):2044-2060.
-
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).
-
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer. J Immunother Cancer. 2024 Oct 20; 12(10).
-
Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art. Expert Opin Biol Ther. 2024 Oct; 24(10):1005-1015.
-
Non-small-cell lung cancer. Nat Rev Dis Primers. 2024 Sep 26; 10(1):71.
-
Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients. Eur J Cancer. 2024 Nov; 212:114336.